6
Jun
2018

From Hoop Dreams to the Biopharma Big Time: Rob Perez on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Medicines Based on Unusual Genetic Traits: Andrew Farnum on The Long Run
Creating the Future of Microbiome-Based Therapies: Simba Gill on The Long Run
The Battle for the Soul of Biopharma: Peter Kolchinsky on The Long Run
Machine Learning for Drug Discovery: Daphne Koller on The Long Run